Dr. Wahlestedt's laboratory pursues drug discovery and evaluation of combination therapies for various cancers. His team has been successful in identifying and bringing forward - towards testing in human - several novel inhibitors of epigenetic and other drug targets. They are also conducting personalized ex vivo drug screening (with the cancer patient's own cells) to aid optimized treatment.